A reduction in CPS1 in HCC may result in increased shunting of glutamine to CAD, which is the initiating step of the de novo pyrimidine synthesis pathway, and may lead to unfavorable outcomes [17]. The gene discussed is CPS1; the disease is hepatocellular carcinoma.